SCHEMBL19084683

SCHEMBL19084683

CSc1ccc(Cc2nn3c(=O)cc(-c4ccc([N+](=O)[O-])cc4)[nH]c3c2-c2ccc(Cl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 5/20 0.55
ARF6 P62330 11/20 0.53
SLC27A2 O14975 1/20 0.41
MAPT P10636 2/20 0.39
MCL1 Q07820 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NR2F2 P24468 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13516218 0.89 ARF6 (0.65) PSDARF6SLC27A2
SCHEMBL19084540 0.88 ARF6 (0.55) PSDARF6SLC27A2MAPTMCL1
SCHEMBL19084585 0.83 PSD (0.55) PSDARF6SLC27A2MAPTMCL1
SCHEMBL19084617 0.83 ARF6 (0.50) PSDARF6SLC27A2MAPTMCL1
SCHEMBL14899468 0.83 ARF6 (0.56) PSDARF6SLC27A2MAPTRAB9A
SCHEMBL17298691 0.81 PSD (0.54) PSDARF6MAPTALDH1A1RAB9A
SCHEMBL19084591 0.80 ARF6 (0.54) PSDARF6SLC27A2
SCHEMBL13516359 0.80 PSD (0.48) PSDARF6SLC27A2MAPTMCL1
SCHEMBL19084689 0.80 PSD (0.52) PSDARF6SLC27A2MAPTMCL1
SCHEMBL14899467 0.80 PSD (0.53) PSDARF6SLC27A2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885SLC27A2 2424/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885SLC27A2 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.